AN2 Therapeutics Q2 EPS $(0.48) Beats $(0.59) Estimate
Portfolio Pulse from Benzinga Newsdesk
AN2 Therapeutics (NASDAQ:ANTX) reported a Q2 EPS loss of $(0.48), beating the analyst consensus estimate of $(0.59) by 18.64%. This represents a 40.74% improvement over the $(0.81) loss per share from the same period last year.
August 13, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AN2 Therapeutics reported a Q2 EPS loss of $(0.48), which is better than the analyst estimate of $(0.59) and shows a significant improvement from last year's $(0.81) loss per share.
The better-than-expected EPS and significant year-over-year improvement are likely to positively impact ANTX's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100